APA

Kumar B. N. P., Puvvada N., Rajput S., Sarkar S., Mahto M. K., Yallapu M. M., Pathak A., Emdad L., Das S. K., Reis R. L., Kundu S. C., Fisher P. B. & Mandal M. (20190624). Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. : Molecular pharmaceutics.

Chicago

Kumar B N Prashanth, Puvvada Nagaprasad, Rajput Shashi, Sarkar Siddik, Mahto Madhusudan Kr, Yallapu Murali M, Pathak Amita, Emdad Luni, Das Swadesh K, Reis Rui L, Kundu S C, Fisher Paul B and Mandal Mahitosh. 20190624. Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. : Molecular pharmaceutics.

Harvard

Kumar B. N. P., Puvvada N., Rajput S., Sarkar S., Mahto M. K., Yallapu M. M., Pathak A., Emdad L., Das S. K., Reis R. L., Kundu S. C., Fisher P. B. and Mandal M. (20190624). Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. : Molecular pharmaceutics.

MLA

Kumar B N Prashanth, Puvvada Nagaprasad, Rajput Shashi, Sarkar Siddik, Mahto Madhusudan Kr, Yallapu Murali M, Pathak Amita, Emdad Luni, Das Swadesh K, Reis Rui L, Kundu S C, Fisher Paul B and Mandal Mahitosh. Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. : Molecular pharmaceutics. 20190624.